Document is current
Any future updates will be listed below
-
Authors
Kelvin, James M.
Jain, Juhi
Thapa, Aashis
Qui, Min
Birnbaum, Lacey A.
Moore, Samuel G.
Zecca, Henry
Summers, Ryan J.
Switchenko, Jeffrey M.
Costanza, Emma
Uricoli, Biaggio
Wang, Xiaodong
Jui, Nathan T.
Fu, Haian
Du, Yuhong
DeRyckere, Deborah
Graham, Douglas K.
Dreaden, Erik C.
-
Funding
Funding for this research was provided by:
CURE Childhood Cancer
NIH Research Training Program in Immunoengineering (T32EB021962)
Wallace H. Coulter Department of Biomedical Engineering
- License Information
-
More Information
Article History
Received: 15 March 2023
Accepted: 26 August 2023
First Online: 13 September 2023
Declarations
:
: D.K.G. is a founder and serves on the Board of Directors of Meryx, Inc. X.W., D.D., and D.K.G. are equity holders in Meryx, Inc. X.W. is an inventor on patents describing MRX-2843. J.M.K., J.J., D.D., D.K.G., and E.C.D. are inventors on a patent describing combination drug nanoformulations related to this work.
